Bristol-Myers Squibb (BMS) has reported strong third quarter results, announcing an 11% increase in revenue to $5.35bn attributed to the company’s blood thinning drug Plavix.
Plavix turnover rose 8% to $1.79bn, while the company also reported increases to its portfolio of HIV drugs, with Sustiva and Reyataz climbing 5% and 4% respectively.
Go deeper with GlobalData
BMS was, however, hit by a 29% fall in sales of Avapro/Avalide, used to treat hypertension.
CEO Lamberto Andreotti hailed the results and also praised data from the company’s trial of the stroke prevention medication Eliquis.
"We are excited by the strength of the Phase III data presented on Eliquis for stroke prevention in patients with atrial fibrillation and by the possibility that Eliquis could play a key role in the company’s future," he said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
